IP Library Granted Patent US 11,464,833
Granted Patent B2
US 11,464,833 · App. 16/479,499 · Granted Oct 11, 2022

Methods for treating or preventing tissue adhesions

Inventors: Michael Boettcher (Hamburg, DE); Tobias Fuchs (Hamburg, DE)
Assignee: NEUTROLIS, INC.
A61K38/465A61P41/00C12Y301/21001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,833
App. No.
16/479,499
Granted
Oct 11, 2022
Kind
B2
Abstract

The present invention relates to the treatment of tissue adhesions, e.g. tissue adhesions that occur after surgical interventions. More specifically, the invention refers to an enzyme having DNAse activity for use in a method of treating or preventing tissue adhesions. The invention also relates to a pharmaceutical composition that comprises an enzyme having DNAse activity for use in a method of treating or preventing tissue adhesions.

Claims (10)

1. A method of treating or preventing tissue adhesion in a subject undergoing abdominal surgery, comprising administering an enzyme having a deoxyribonuclease (DNase) activity to the subject as a solution one or more times during surgery directly to tissue or organ surfaces injured during the surgery that are at risk of forming adhesions, wherein the enzyme is a human DNase-1-like 3, wherein said human DNase-1-like 3 comprises the amino acid sequence of SEQ ID NO: 6, or a sequence having at least 95% sequence identity thereto, wherein said method does not involve the administration of plasmin.

2. The method of claim 1 , wherein said method comprises the administration of between 1,000 to 10,000 Units (U) of the enzyme to the subject.

3. The method of claim 1 , wherein said method comprises the administration of the enzyme between 0.15 mg per kg body weight of the subject to 200 mg per kg body weight.

4. The method of claim 1 , wherein the enzyme is a recombinantly produced enzyme.

5. The method of claim 1 , wherein the surgery is hernia repair.

6. The method of claim 1 , wherein the surgery involves intestinal anastomosis.

7. The method of claim 1 , wherein the surgery is cesarean section.

8. The method of claim 1 , wherein the surgical intervention involves damaging of a serous membrane.

9. The method of claim 8 , wherein the serous membrane is a peritoneal membrane.

10. The method of claim 1 , wherein the subject suffers from a thermal lesion in a serous membrane.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2022
From: BOETTCHER, MICHAEL; FUCHS, TOBIAS A.
To: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
Reel/Frame 060938/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2022
From: UNIVERSITY MEDICAL CENTER HAMBURG-EPPENDORF
To: NEUTROLIS THERAPEUTICS, INC.
Reel/Frame 060938/0920 →
CHANGE OF NAME Recorded Aug 30, 2022
From: NEUTROLIS THERAPEUTICS, INC.
To: NEUTROLIS, INC.
Reel/Frame 061357/0215 →
Priority Claims (1)
EP 17152341 · Jan 20, 2017 · regional
Continuity (1)
Related Publication 20190374620A1 · Dec 12, 2019